The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China ...

Illumina (ILMN) responded to the March 4 notice from the China Ministry of Commerce that the company is not permitted to export sequencing ...

Next-generation sequencing (NGS) technology, which has been used at Illumina since 2007, builds upon earlier genome sequencing methods to greatly reduce the time taken to sequence DNA. When the ...

Amid increasing economic tensions with the United States, China recently announced that it would ban Illumina, a U.S.-based company and the ...

Illumina said at the time that it was working to find a solution. “We respect and abide by Chinese laws and regulations,” the ...

Illumina aims to transform human health practices through its leadership of genomic sequencing and related applications. The firm provides a broad range of instruments and related consumables to ...

Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

China banned the import of Illumina Inc. gene-sequencing machines as part of a wave of retaliatory measures against fresh US tariffs on all Chinese goods, deepening the US company’s woes in one ...

"Disease doesn't wait, and neither do we – Broad Clinical Labs and Illumina are unlocking the massive opportunities of single-cell sequencing to build a deeper understanding of biology," said ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad ...